<p>Nekton Capital Ltd. 在其最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第四季度购买了 Enfusion, Inc.（NYSE:ENFN - 免费报告）的新股份。该基金购买了 43,611 股公司股票，价值约 449,000 美元。Enfusion 大约占 Nekton Capital Ltd. 投资组合的 1.2%，使其成为第七大持股。</p>
<p>其他一些机构投资者和对冲基金最近也增加或减少了对该公司的持股。KLP Kapitalforvaltning AS 在第四季度以约 75,000 美元的价格收购了 Enfusion 的新股份。Tower Research Capital LLC TRC 在第四季度将其在 Enfusion 的股份增加了 58.6%。Tower Research Capital LLC TRC 现在拥有 13,227 股公司股票，价值 136,000 美元，此前在上个季度又收购了 4,889 股。Quantbot Technologies LP 在第四季度以 144,000 美元的价格收购了 Enfusion 的新股份。Intech Investment Management LLC 在第四季度以 191,000 美元的价格收购了 Enfusion 的新股份。最后，Wells Fargo &amp; Company MN 在第四季度将其在 Enfusion 的持股增加了 46.8%。Wells Fargo &amp; Company MN 现在拥有 25,499 股公司股票，价值 263,000 美元，此前在上个季度又购买了 8,126 股。81.05% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师对 ENFN 股票发布了报告。Piper Sandler 将 Enfusion 的目标价从 10.00 美元上调至 11.50 美元，并在 12 月 23 日的报告中给予该股票 &#34;中性&#34; 评级。William Blair 在 1 月 13 日的报告中重申了对 Enfusion 股票的 &#34;市场表现&#34; 评级。</p>
<p><strong>获取我们关于 ENFN 的最新报告</strong></p>
<h2>Enfusion 的内部买卖</h2>
<p>在相关消息中，首席运营官 Neal Pawar 于 3 月 3 日星期一出售了 2,769 股公司的股票，交易价格为每股平均 11.48 美元，总价值为 31,788.12 美元。交易完成后，首席运营官现在拥有 1,231,627 股公司股票，价值约 14,139,077.96 美元。这笔交易使其持股减少了 0.22%。该出售在向 SEC 提交的文件中披露，您可以通过此链接访问。此外，首席执行官 Oleg Movchan 于 3 月 3 日星期一出售了 2,790 股股票，交易价格为每股平均 11.48 美元，总价值为 32,029.20 美元。交易完成后，首席执行官现在拥有 643,299 股公司股票，价值 7,385,072.52 美元。这代表其持股减少了 0.43%。该出售的披露信息可以在这里找到。内部人士在上个季度出售了 66,223 股公司股票，价值 754,778 美元。公司内部人士持有 36.44% 的公司股票。</p>
<h2>Enfusion 股票上涨 0.5%</h2>
<p>ENFN 股票在周二开盘价为 10.85 美元。该公司的市值为 14 亿美元，市盈率为 271.29，市盈增长比率为 1.85，贝塔值为 0.92。Enfusion, Inc. 的一年低点为 7.83 美元，一年高点为 11.80 美元。该股票的 50 日简单移动平均线为 11.07 美元，200 日简单移动平均线为 10.44 美元。</p>
<p>Enfusion（NYSE:ENFN - 获取免费报告）最近于 3 月 3 日星期一发布了其财报。该公司报告本季度每股收益为 0.01 美元，低于分析师一致预期的 0.03 美元，差距为 0.02 美元。Enfusion 的净利润率为 1.70%，股本回报率为 6.67%。该公司本季度的收入为 5294 万美元，而分析师预期为 5398 万美元。平均而言，卖方分析师预测 Enfusion, Inc. 本年度将发布 0.06 的每股收益。</p>
<h2>关于 Enfusion</h2>
<p>（免费报告）</p>
<p>Enfusion, Inc. 为美国、欧洲、中东、非洲和亚太地区的投资管理行业提供软件即服务解决方案。该公司提供投资组合管理系统，生成实时投资记录，包括估值和风险工具，使用户能够分析首席投资官（CIO）和投资组合经理的汇总或分解投资组合数据；以及订单和执行管理系统，使投资组合经理、交易员、合规团队和分析师能够电子沟通各种资产类别的交易订单，管理交易订单，并系统性地执行交易法规和内部指南。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Enfusion 更好</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>AST SpaceMobile：购买这只小型开拓者股票的五个理由</li>
<li>支撑与阻力的基础知识</li>
<li>为什么看涨期权交易者现在瞄准这个分红 ETF</li>
<li>什么是日经 225 指数？</li>
<li>Alphabet 被误解了吗？这就是为什么多头在买入</li>
</ul>
<p><strong>想看看其他对冲基金持有 ENFN 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Enfusion, Inc.（NYSE:ENFN - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVORk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVORk4"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Enfusion 吗？</h2>
<p>在考虑 Enfusion 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Enfusion 并不在名单上。</p>
<p>虽然 Enfusion 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ENFN

<p>Nekton Capital Ltd. 在第四季度收购了 43,611 股 Enfusion, Inc.（纽约证券交易所代码：ENFN），价值约为 449,000 美元，使其成为该投资组合中第七大持股。其他机构投资者也增加了他们的持股。分析师们提高了对 ENFN 的目标价格，Piper Sandler 将其设定为 11.50 美元。Enfusion 报告第四季度每股收益为 0.01 美元，未达到预期，收入为 5294 万美元。该股票开盘价为 10.85 美元，市值为 14 亿美元，市盈率为 271.29</p>

<p>Nekton Capital Ltd. bought a new position in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 43,611 shares of the company's stock, valued at approximately $449,000. Enfusion makes up approximately 1.2% of Nekton Capital Ltd.'s investment portfolio, making the stock its 7th largest holding.</p>
<div class="lb-trans"><p>Nekton Capital Ltd. 在其最近向证券交易委员会（SEC）提交的 13F 表格中表示，在第四季度购买了 Enfusion, Inc.（NYSE:ENFN - 免费报告）的新股份。该基金购买了 43,611 股公司股票，价值约 449,000 美元。Enfusion 大约占 Nekton Capital Ltd. 投资组合的 1.2%，使其成为第七大持股。</p>
</div><p>A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in Enfusion during the fourth quarter valued at approximately $75,000. Tower Research Capital LLC TRC boosted its stake in shares of Enfusion by 58.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company's stock worth $136,000 after acquiring an additional 4,889 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Enfusion in the 4th quarter worth $144,000. Intech Investment Management LLC acquired a new stake in shares of Enfusion during the fourth quarter worth $191,000. Finally, Wells Fargo &amp; Company MN lifted its holdings in shares of Enfusion by 46.8% during the fourth quarter. Wells Fargo &amp; Company MN now owns 25,499 shares of the company's stock valued at $263,000 after purchasing an additional 8,126 shares during the last quarter. 81.05% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也增加或减少了对该公司的持股。KLP Kapitalforvaltning AS 在第四季度以约 75,000 美元的价格收购了 Enfusion 的新股份。Tower Research Capital LLC TRC 在第四季度将其在 Enfusion 的股份增加了 58.6%。Tower Research Capital LLC TRC 现在拥有 13,227 股公司股票，价值 136,000 美元，此前在上个季度又收购了 4,889 股。Quantbot Technologies LP 在第四季度以 144,000 美元的价格收购了 Enfusion 的新股份。Intech Investment Management LLC 在第四季度以 191,000 美元的价格收购了 Enfusion 的新股份。最后，Wells Fargo &amp; Company MN 在第四季度将其在 Enfusion 的持股增加了 46.8%。Wells Fargo &amp; Company MN 现在拥有 25,499 股公司股票，价值 263,000 美元，此前在上个季度又购买了 8,126 股。81.05% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have issued reports on ENFN shares. Piper Sandler boosted their price objective on Enfusion from $10.00 to $11.50 and gave the stock a &#34;neutral&#34; rating in a report on Monday, December 23rd. William Blair restated a &#34;market perform&#34; rating on shares of Enfusion in a report on Monday, January 13th.</p>
<div class="lb-trans"><p>几位分析师对 ENFN 股票发布了报告。Piper Sandler 将 Enfusion 的目标价从 10.00 美元上调至 11.50 美元，并在 12 月 23 日的报告中给予该股票 &#34;中性&#34; 评级。William Blair 在 1 月 13 日的报告中重申了对 Enfusion 股票的 &#34;市场表现&#34; 评级。</p>
</div><p><strong>Get Our Latest Report on ENFN</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 ENFN 的最新报告</strong></p>
</div><h2>Insider Buying and Selling at Enfusion</h2>
<div class="lb-trans"><h2>Enfusion 的内部买卖</h2>
</div><p>In related news, COO Neal Pawar sold 2,769 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $31,788.12. Following the completion of the sale, the chief operating officer now owns 1,231,627 shares of the company's stock, valued at approximately $14,139,077.96. The trade was a 0.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Oleg Movchan sold 2,790 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $32,029.20. Following the completion of the transaction, the chief executive officer now owns 643,299 shares in the company, valued at $7,385,072.52. This represents a 0.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,223 shares of company stock valued at $754,778 in the last quarter. Company insiders own 36.44% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席运营官 Neal Pawar 于 3 月 3 日星期一出售了 2,769 股公司的股票，交易价格为每股平均 11.48 美元，总价值为 31,788.12 美元。交易完成后，首席运营官现在拥有 1,231,627 股公司股票，价值约 14,139,077.96 美元。这笔交易使其持股减少了 0.22%。该出售在向 SEC 提交的文件中披露，您可以通过此链接访问。此外，首席执行官 Oleg Movchan 于 3 月 3 日星期一出售了 2,790 股股票，交易价格为每股平均 11.48 美元，总价值为 32,029.20 美元。交易完成后，首席执行官现在拥有 643,299 股公司股票，价值 7,385,072.52 美元。这代表其持股减少了 0.43%。该出售的披露信息可以在这里找到。内部人士在上个季度出售了 66,223 股公司股票，价值 754,778 美元。公司内部人士持有 36.44% 的公司股票。</p>
</div><h2>Enfusion Trading Up 0.5 %</h2>
<div class="lb-trans"><h2>Enfusion 股票上涨 0.5%</h2>
</div><p>Shares of ENFN stock opened at $10.85 on Tuesday. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 271.29, a P/E/G ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 1-year low of $7.83 and a 1-year high of $11.80. The stock's fifty day simple moving average is $11.07 and its 200-day simple moving average is $10.44.</p>
<div class="lb-trans"><p>ENFN 股票在周二开盘价为 10.85 美元。该公司的市值为 14 亿美元，市盈率为 271.29，市盈增长比率为 1.85，贝塔值为 0.92。Enfusion, Inc. 的一年低点为 7.83 美元，一年高点为 11.80 美元。该股票的 50 日简单移动平均线为 11.07 美元，200 日简单移动平均线为 10.44 美元。</p>
</div><p>Enfusion (NYSE:ENFN - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The business had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. On average, sell-side analysts predict that Enfusion, Inc. will post 0.06 EPS for the current year.</p>
<div class="lb-trans"><p>Enfusion（NYSE:ENFN - 获取免费报告）最近于 3 月 3 日星期一发布了其财报。该公司报告本季度每股收益为 0.01 美元，低于分析师一致预期的 0.03 美元，差距为 0.02 美元。Enfusion 的净利润率为 1.70%，股本回报率为 6.67%。该公司本季度的收入为 5294 万美元，而分析师预期为 5398 万美元。平均而言，卖方分析师预测 Enfusion, Inc. 本年度将发布 0.06 的每股收益。</p>
</div><h2>About Enfusion</h2>
<div class="lb-trans"><h2>关于 Enfusion</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.</p>
<div class="lb-trans"><p>Enfusion, Inc. 为美国、欧洲、中东、非洲和亚太地区的投资管理行业提供软件即服务解决方案。该公司提供投资组合管理系统，生成实时投资记录，包括估值和风险工具，使用户能够分析首席投资官（CIO）和投资组合经理的汇总或分解投资组合数据；以及订单和执行管理系统，使投资组合经理、交易员、合规团队和分析师能够电子沟通各种资产类别的交易订单，管理交易订单，并系统性地执行交易法规和内部指南。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Enfusion</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock</li>
<li>The Basics of Support and Resistance</li>
<li>Why Call Option Traders Are Targeting This Dividend ETF Now</li>
<li>What is the Nikkei 225 index?</li>
<li>Is Alphabet Misunderstood? Here’s Why the Bulls Are Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Enfusion 更好</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>AST SpaceMobile：购买这只小型开拓者股票的五个理由</li>
<li>支撑与阻力的基础知识</li>
<li>为什么看涨期权交易者现在瞄准这个分红 ETF</li>
<li>什么是日经 225 指数？</li>
<li>Alphabet 被误解了吗？这就是为什么多头在买入</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ENFN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enfusion, Inc. (NYSE:ENFN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 ENFN 的情况吗？</strong> 访问 HoldingsChannel.com 获取 Enfusion, Inc.（NYSE:ENFN - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVORk4" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ENFN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Enfusion Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Enfusion 吗？</h2>
</div><p>Before you consider Enfusion, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Enfusion 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Enfusion 并不在名单上。</p>
</div><p>While Enfusion currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Enfusion 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Nekton Capital Ltd. 在 Enfusion, Inc. (NYSE:ENFN) 中建立了投资头寸